Mesoblast Limited (MSB.AX)
AUD 3.05
(54.04%)
AUD 3.05
(54.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 188.79 Million USD | 12.66% |
| 2023 | 167.57 Million USD | 1.5% |
| 2022 | 165.09 Million USD | 1.09% |
| 2021 | 163.32 Million USD | -11.37% |
| 2020 | 184.27 Million USD | 7.72% |
| 2019 | 171.06 Million USD | 16.82% |
| 2018 | 146.43 Million USD | 5.41% |
| 2017 | 138.92 Million USD | -10.87% |
| 2016 | 155.85 Million USD | -61.85% |
| 2015 | 408.56 Million USD | 24.72% |
| 2014 | 327.59 Million USD | 29.26% |
| 2013 | 253.44 Million USD | 4.9% |
| 2012 | 241.6 Million USD | -2.34% |
| 2011 | 247.4 Million USD | 15406.41% |
| 2010 | 1.59 Million USD | 34.64% |
| 2009 | 1.18 Million USD | -24.65% |
| 2008 | 1.57 Million USD | 125.04% |
| 2007 | 698.89 Thousand USD | -84.19% |
| 2006 | 4.41 Million USD | 100.61% |
| 2005 | 2.2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 161.55 Million USD | -3.59% |
| 2024 FY | 188.79 Million USD | 12.66% |
| 2024 Q4 | 188.79 Million USD | 0.0% |
| 2024 Q2 | 161.55 Million USD | 0.0% |
| 2023 Q2 | 168.05 Million USD | 3.94% |
| 2023 Q4 | 167.57 Million USD | -0.41% |
| 2023 FY | 167.57 Million USD | 1.5% |
| 2023 Q3 | 168.27 Million USD | 0.13% |
| 2023 Q1 | 161.68 Million USD | -2.06% |
| 2022 Q2 | 168.93 Million USD | 4.23% |
| 2022 Q1 | 162.07 Million USD | -0.76% |
| 2022 Q3 | 164.56 Million USD | -2.59% |
| 2022 Q4 | 165.09 Million USD | 0.33% |
| 2022 FY | 165.09 Million USD | 1.09% |
| 2021 Q3 | 165.19 Million USD | -2.01% |
| 2021 FY | 163.32 Million USD | -11.37% |
| 2021 Q1 | 174.06 Million USD | -5.54% |
| 2021 Q2 | 168.57 Million USD | -3.15% |
| 2021 Q4 | 163.32 Million USD | -1.14% |
| 2020 Q1 | 178.63 Million USD | 4.43% |
| 2020 Q2 | 189.43 Million USD | 6.04% |
| 2020 Q3 | 177.97 Million USD | -6.05% |
| 2020 Q4 | 184.27 Million USD | 3.54% |
| 2020 FY | 184.27 Million USD | 7.72% |
| 2019 Q4 | 171.06 Million USD | -2.12% |
| 2019 Q3 | 174.76 Million USD | 6.71% |
| 2019 Q2 | 163.77 Million USD | 1.6% |
| 2019 Q1 | 161.19 Million USD | 10.08% |
| 2019 FY | 171.06 Million USD | 16.82% |
| 2018 Q4 | 146.43 Million USD | 20.3% |
| 2018 FY | 146.43 Million USD | 5.41% |
| 2018 Q3 | 121.72 Million USD | 36.45% |
| 2018 Q2 | 89.2 Million USD | -20.57% |
| 2018 Q1 | 112.3 Million USD | -19.16% |
| 2017 Q1 | 155.57 Million USD | -0.18% |
| 2017 FY | 138.92 Million USD | -10.87% |
| 2017 Q4 | 138.92 Million USD | 0.12% |
| 2017 Q3 | 138.75 Million USD | -7.72% |
| 2017 Q2 | 150.36 Million USD | -3.35% |
| 2016 Q2 | 298.19 Million USD | 638.12% |
| 2016 Q1 | 40.4 Million USD | -90.11% |
| 2016 FY | 155.85 Million USD | -61.85% |
| 2016 Q4 | 155.85 Million USD | -46.48% |
| 2016 Q3 | 291.2 Million USD | -2.34% |
| 2015 Q2 | 379.7 Million USD | 901.04% |
| 2015 Q1 | 37.93 Million USD | -88.42% |
| 2015 FY | 408.56 Million USD | 24.72% |
| 2015 Q4 | 408.56 Million USD | 0.0% |
| 2015 Q3 | - USD | -100.0% |
| 2014 Q3 | 39.56 Million USD | -89.11% |
| 2014 FY | 327.59 Million USD | 29.26% |
| 2014 Q2 | 363.33 Million USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2014 Q4 | 327.59 Million USD | 727.95% |
| 2013 Q3 | 52.65 Million USD | -76.79% |
| 2013 FY | 253.44 Million USD | 4.9% |
| 2013 Q4 | 253.44 Million USD | 381.34% |
| 2013 Q1 | 235.42 Million USD | -2.56% |
| 2013 Q2 | 226.89 Million USD | -3.62% |
| 2012 FY | 241.6 Million USD | -2.34% |
| 2012 Q4 | 241.6 Million USD | 0.0% |
| 2011 FY | 247.4 Million USD | 15406.41% |
| 2010 FY | 1.59 Million USD | 34.64% |
| 2009 FY | 1.18 Million USD | -24.65% |
| 2008 FY | 1.57 Million USD | 125.04% |
| 2007 FY | 698.89 Thousand USD | -84.19% |
| 2006 FY | 4.41 Million USD | 100.61% |
| 2005 FY | 2.2 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -4364.212% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -61427.983% |
| Zelira Therapeutics Limited | 9.35 Million AUD | -1917.808% |
| Biome Australia Limited | 5.37 Million AUD | -3413.656% |
| Patrys Limited | 691.36 Thousand AUD | -27208.007% |
| Orthocell Limited | 22.08 Million AUD | -754.961% |
| Imugene Limited | 33.14 Million AUD | -469.64% |
| Noxopharm Limited | 1.28 Million AUD | -14551.245% |
| PYC Therapeutics Limited | 10.18 Million AUD | -1753.852% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | -1374.629% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -8018.378% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -11511.729% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -16022.044% |
| CSL Limited | 27.88 Billion AUD | 99.323% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -9079.942% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -51141.702% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | -571.588% |
| Starpharma Holdings Limited | 8.69 Million AUD | -2070.591% |
| Nanollose Limited | 465.64 Thousand AUD | -40445.654% |
| Memphasys Limited | 5.59 Million AUD | -3275.979% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -43640.704% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -220244.759% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -5409.456% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -4958.792% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -17956.012% |
| Race Oncology Limited | 1.91 Million AUD | -9751.573% |
| Nyrada Inc. | 855.63 Thousand AUD | -21965.301% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 24.296% |
| Dimerix Limited | 13.89 Million AUD | -1258.94% |
| PharmAust Limited | 896.6 Thousand AUD | -20956.94% |
| Immutep Limited | 10.97 Million AUD | -1619.534% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | -2166.005% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -3379.707% |
| BTC Health Limited | 203.94 Thousand AUD | -92471.636% |
| Acrux Limited | 5.68 Million AUD | -3219.817% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | -341.498% |
| Biotron Limited | 737.5 Thousand AUD | -25499.451% |
| Tissue Repair Ltd | 1.35 Million AUD | -13875.679% |
| AdAlta Limited | 3.54 Million AUD | -5229.43% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | -322.527% |
| Hexima Limited | 248.67 Thousand AUD | -75823.111% |
| AnteoTech Limited | 4.07 Million AUD | -4532.788% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -5167.3% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | -1087.903% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -19952.042% |
| Actinogen Medical Limited | 1.61 Million AUD | -11587.615% |
| Immuron Limited | 2.84 Million AUD | -6546.588% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -7679.966% |